A simple blood test could revolutionize early Alzheimer’s detection, offering a less invasive and highly accurate tool to identify people at risk before symptoms appear.
Study: A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer’s disease. Image Credit: ART-ur / Shutterstock
In a recent study published in the journal eBioMedicine, researchers evaluated the performance of plasma biomarkers to detect amyloid-β (Aβ) pathology in cognitively unimpaired (CU) individuals.
The preclinical stage of Alzheimer’s disease (AD) is a period when the accumulation of phosphorylated tau (p-tau) and Aβ begins to occur, but cognitive impairment is not yet evident. Accurate in vivo detection of this stage…